Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JNJ with free AI briefings, catalyst countdowns, and dilution alerts.

JNJ · Johnson & Johnson

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$20.4B Cash on Hand
CF+ Cash Runway
0.8% Short Interest
$280.18 Analyst Target (22)
Follow JNJ by email Get an email when JNJ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JNJ, unsubscribe in one click. Privacy

📣 What JNJ Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Teclistamab
FDA approved Oct 2022 · Tecvayli
Multiple Myeloma Phase 4 · NCT07030517 Active not recruiting
Talquetamab
FDA approved Aug 2023 · Talvey
Multiple Myeloma (MM) Phase 3 · NCT07649525 Recruiting
Daratumumab
FDA approved Nov 2015 · Darzalex
Multiple Myeloma (MM) Phase 3 · NCT07649525 Recruiting
Hafnium Oxide-containing Nanoparticles NBTXR3 Carcinoma, Squamous Cell Phase 3 · NCT04892173 Recruiting
Infliximab Cytokine Release Syndrome Phase 2 · NCT07657312 Recruiting
JNJ-1761981 Neoplasms Phase 1 · NCT07525141 Recruiting
Adenosine A2A Receptor Antagonist JNJ-86974680 Carcinoma, Non-small-Cell Lung Phase 1 · NCT06116786 Active not recruiting
Oncolytic HSV-1 JNJ-87704916 Neoplasms Phase 1 · NCT06311578 Recruiting
Mezigdomide Multiple Myeloma Phase 1 · NCT07105059 Recruiting
Cetrelimab Neoplasms Phase 1 · NCT07525141 Recruiting
Pasritamig Prostate Cancer Phase 1 · NCT07860255 Not yet recruiting

Also used in these trials (approved or third-party drugs, not JNJ's own candidates): Acetaminophen, Naproxen Sodium 220Mg, Lenalidomide, Dexamethasone, Cetuximab, Durvalumab, Cisplatin, Paclitaxel, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

JNJ holds $20.4B in cash and short-term investments (as of Sep 27, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JNJ files for a raise →

👥 Who Owns JNJ

Insiders 0% Institutions (5882 holders) 77% Public and other holders 23%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 209,718,001 8.71% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 180,631,228 7.50% 2026-03-31
State Street Corporation Institution (13F) 133,971,339 5.57% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 65,651,392 2.73% 2026-09-30
Geode Capital Management, LLC Institution (13F) 65,497,363 2.72% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 61,752,701 2.57% 2026-09-30
Morgan Stanley Institution (13F) 44,682,305 1.86% 2026-09-30
State Farm Mutual Automobile Insurance C Institution (13F) 31,590,952 1.31% 2026-09-30
Northern Trust Corporation Institution (13F) 28,197,333 1.17% 2026-09-30
Joaquin Duato
CEO and Chairman of the Board, Director
Insider 307,837 0.01% 2026-08-13
Jennifer L Taubert
EVP, WWC. Innovative Medicine · +87,521 options
Insider 194,451 0.01% 2026-08-17
Kathryn E Wengel
EVP, Chief TO and Risk Officer · +51,127 options
Insider 114,659 0.00% 2026-06-11

Share count 2,407,310,266 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-12
filed 2026-11-13
Forminard Elizabeth
Option exercise (M) 13,072 $151.41 30,066
2026-11-12
filed 2026-11-13
Forminard Elizabeth
Sale (S) 13,072 $284.39 16,994
2026-11-12
filed 2026-11-13
Forminard Elizabeth
Option exercise (M) 13,072 – –
2026-09-08
filed 2026-09-10
Pinto Daniel E
Option award (A) 113 $276.31 –
2026-09-08
filed 2026-09-10
Woods Eugene A.
Option award (A) 136 $276.31 –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full JNJ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JNJ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.